One person died of an e. coli infection resulting from a dung transplant, and the US government warns that this could happen again.
The Food and Drug Administration on Thursday issued a bulletin warning of possible complications of fecal microbiota transplantation (FMT), which is gaining popularity for the treatment of C. diff, a debilitating intestinal infection.
"The agency is now aware of bacterial infections caused by drug-resistant microorganisms (MDROs) due to the transmission of an MDRO resulting from the use of a drug. Experimental FMT, "said the FDA.
"Patients considering an FMT It's hard the infection should talk to its health care provider to understand the potential risks associated with the use of the product. "
Dr. Sahil Khanna, a gastroenterologist at the Mayo Clinic who performs stool transplants, told NBC News that it was probably the first death of an FMT procedure.
Nevertheless, the procedure may work as well as traditional antibiotics in the treatment of C. diff, which, according to the Center for Disease Control and Prevention, infects 500,000 patients each year, many of whom relapse soon after. In patients over 65, nearly 10% died of the infection.
"Recently, fecal microbiota transplantation has proven effective in the treatment of recurrent diseases. It's hard infection, "a study published in the New England Journal of Medicine in 2018. The trials showed that FMT worked as well as antibiotics to treat C. diff.
"This was a small trial, but the results suggest that fecal microbiota transplantation could be an alternative to first-line antibiotic therapy. It's hard infection, "wrote the authors.
Read more: uBiome convinced Silicon Valley that shit tests were worth $ 600 million. Then the FBI came to knock on the door. Here is the story inside.
But after the death and illness of a recent patient, the FDA warned against strengthening protections. Donor screening tests are necessary to prevent others from getting infections from MDRO.
"Patients who are considering an FMT to treat It's hard the infection must talk to its health care provider to understand the potential risks associated with the use of the product, "said the FDA.